Lutropin Alfa

證據等級: L5

預測適應症: 10 個

Lutropin alfa: From Original Indication Not Documented to Postural Orthostatic Tachycardia Syndrome

One-Sentence Summary

Lutropin alfa (DrugBank DB00044, recombinant human luteinizing hormone) currently has no documented original indication or mechanism-of-action data in this Evidence Pack — both are flagged as data gaps. The TxGNN model predicts potential activity in Postural Orthostatic Tachycardia Syndrome (POTS), but this prediction is currently supported by 0 clinical trials and 0 publications.

Quick Overview

Item	Content
Original Indication	Not documented (no indication data captured; drug is not marketed in Denmark)
Predicted New Indication	Postural Orthostatic Tachycardia Syndrome
TxGNN Prediction Score	97.04%
Evidence Level	L5 (model prediction only, no clinical trials or literature)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Lutropin alfa in this Evidence Pack (flagged as a High-severity data gap, DG002). Based on the model’s own rationale, Lutropin alfa is a recombinant form of human luteinizing hormone (LH), which acts on the LHCGR receptor to stimulate gonadal (ovarian/testicular) steroidogenesis.

The proposed link to POTS is that this syndrome is a disorder of autonomic nervous system regulation that predominantly affects premenopausal women and has been loosely associated with estrogen fluctuation. However, there is no direct evidence in the literature connecting LH signaling to autonomic or peripheral vascular regulation — the mechanistic link is characterized in the model’s own rationale as speculative, not supported by a known receptor or pathway relationship.

Because the drug’s original indication is also undocumented in this pack, it is not currently possible to assess similarity between the (unknown) original indication and POTS. This prediction should be treated as a hypothesis generated purely from the TxGNN knowledge graph, pending independent mechanistic or clinical validation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Lutropin alfa is not currently marketed in Denmark — no marketing authorisations (national via Laegemiddelstyrelsen or centralised via EMA) are recorded in this Evidence Pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No key warnings, contraindications, or drug–drug interaction data are currently available in this Evidence Pack; a query for interaction data returned no results.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests solely on a TxGNN model score (Evidence Level L5) with no supporting clinical trials, literature, or established mechanistic pathway — the model’s own rationale describes the drug–disease link as speculative. The drug is also not marketed in Denmark and has a Blocking-severity data gap on SmPC warnings/contraindications, which by itself prevents any safety pre-assessment (S1 stage).

To proceed, the following is needed:

SmPC/product labeling data (warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism of action and original indication documentation — currently a High-severity data gap (DG002)
Preclinical or mechanistic studies establishing biological plausibility for LH involvement in autonomic/vascular regulation
Any emerging clinical trial or case-report evidence specific to POTS (or the other predicted indications: peptic esophagitis, trichotillomania, Raynaud disease, duodenal ulcer)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.